The Boehringer Ingelheim High Expression Technology (BI-HEX®) is an established high expression technology platform that facilitates fast-track development of high-quality, high-titer processes for production of biopharmaceuticals from mammalian cell cultures (CHO cells).
The integrated state-of-the-art technology platform, BI-HEX®, encompasses:
The very robust cell lines grow in chemically defined serum-free media from day one. We achieve record specific productivities of up to 100 pg/cell/day and titers up to 8 g/L. Through early integration of analytical methods a fast assessment of product quality is possible. Furthermore, the extended CHO host cell portfolio allows the best product fit—a perfect match for second-generation processes. Your cell line can be generated in as few as seven months.
In total, more than 40 BI-HEX® cell line development programs have been completed and material produced using this method was sufficient to meet the supply requirements for conducting Phase III clinical trials.